1. HBV Management in 2012… Where Are We Heading?

2. Management of Chronic Hepatitis B

4. Unanswered Questions from the REVEAL

5. 27 Year Follow-up on Maori population in New Zealand with Genotype D

6. 9 Year Natural History Study of CHB Patients in the United States

7. Independent Factors Associated with Disease Progression and HCC

9. Patients Who Developed Serious Liver-related Complicationsa May Be Excluded from Treatment by Current Guidelines/Algorithms

10. Evaluate CHB Patients for Treatment

11. Liver Biopsy for Treatment Candidate Selection

12. Fibro Test: Indeterminate rates ~ 50%

13. FibroScan®

14. Evaluation on Patients in the Gray Zone

15. Recommendations for First-Line Therapy in Patients Without Cirrhosis

17. Change in Ishak Scores at Year 3-7 of Entecavir Therapy by Baseline Fibrosis Score

19. Suboptimal Response to Entecavir Therapy

22. Change in Ishak Scores at Year 5 of Tenofovir Therapy by Baseline Fibrosis Score

23. No Patient with Persistent Viremia During Year 5 Analysis for Tenofovir Therapy

24. Combining ETV and TDF vs. ETV Therapy

25. HBsAg Loss in HBeAg-Positive and HBeAg-Negative Patients

26. Phase I/II Study of a Potent HBsAg Release Inhibitor: REP 9AC

27. REP 9AC Study Results

28. Immunophrophylaxis failure rates of the infants born to mothers with different virologic features

29. Lamivudine Therapy for the Prevention of Vertical Transmission During Pregnancy

31. Elective Cesareans Delivery and Risk of Perinatal Transmission of HBV

33. Where Are We Heading?

34. Thank You!